Yes, kad. There's something going on here and I don't know what it is, but I think that it is the "extra step" that the FDA will be able to point to, to show the world that they were very careful before allowing widespread use of PBT2.
GLTA longs of good will.
J Neurochem. 2011 Oct;119(1):220-30. doi: 10.1111/j.1471-4159.2011.07402.x. Epub 2011 Aug 25.
The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity.
The FDA's partial clinical hold defies logic, which means something else is going on here. The question is, what.
Being an optimist, my hope is that the FDA is BOTH buying some time AND covering their collective #$%$%# before allowing immediate use of PBT2 in Huntington's during concurrent Phase 3. GLTA longs.
When the partial clinical hold is lifted, and/or parkinson's trial starts, and/or Tanzi's Alz-in-a-dish paper is published, and/or, and/or..........many people will be trying to buy all of the few remaining shares, and we know what that means.
From today's press release, and I couldn't agree more--
In order to efficiently advance product candidates through the clinical trial process, we have historically created operating subsidiaries for each program and product line. This approach has fostered efficient use of resources and reduced shareholder dilution as compared to strategies commonly deployed by the biotechnology industry...
The science here is stellar. And the potential market is truly epic. Risk reward at this price--best I've seen. JMHO, of course.
Yes, I've seen cancellations before too. The company cancels when news changes.
Hope it happens here, but if it doesn't, I'll be a buyer again after the split because the few precious shares will be quite expensive after the partial clinical hold is lifted--as I am confident it will be.
Tanzi's publication of dish results and a number of other things could change the outlook dramatically as well.
That's absolutely right, oddusual. I'm sure that every scientist and biostatistician recognizes this--but this is a stock message board. HAHAHA
Still feeling good about the future. GLTA longs of good will.
Been investing long enough to know opportunity when I see it. I'm long term and it's the science that keeps me here and the science hasn't changed.
I agree, wcamp. Anyone who has invested in biotech for awhile has seen this all before. The science is what matters, even though the infestation of this board would have you believe otherwise. Wall Street and the vermin who infest it contribute nothing but suck the lifeblood of the companies who hope to do some good.
I'm here for the science and I'm sticking around until I see reason to doubt it. So far all the news confirms it instead. GLTA longs.
Yes, this was the dream scenario that I was talking about a month or two ago. Vaclav Havel said, "Never hope against hope."
This entire arrangement--my BTX warrants, my free AST shares, my additional BTX warrants (after the spin-off) and now perhaps my additional AST warrants --strikes me as a very clever way to reward long-term and long-suffering Geron investors. I'm feeling very hopeful about the future.
The FDA covering their collective #$%$%# before allowing pre-symptomatic use of PBT2 for Huntington's would be another possibility for an optimist like myself.
Well, there were these words from one of the world's 4 or 5 most important researchers in the field at the most recent AGM
"In closing, based on recent findings, I firmly believe, that beta-amyloid remains the best
target for preventing and treating AD, but this must be achieved in the earliest stages of the
disease process. Based on the combined data, I continue to believe that PBT2 carries great
potential for curbing plaque and tangle formation, while also enhancing neuronal cell viability
as an AD therapeutic."